Vertex Pharmaceuticals Inc (VRTX)
NASDAQ · Healthcare · Biotechnology
Vertex Pharmaceuticals Inc is a Healthcare company with a market capitalization of $124.70B and a trailing P/E ratio of 29.2.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 4, 2026 | $4.47 | $4.31 | +3.8% |
| Q4 2025 | February 12, 2026 | $5.03 | $5.15 | -2.3% |
| Q3 2025 | November 3, 2025 | $4.80 | $4.58 | +4.8% |
| Q2 2025 | August 4, 2025 | $4.52 | $4.25 | +6.3% |
| Q1 2025 | May 5, 2025 | $2.49 | $3.76 | -33.8% |
| Q4 2024 | February 10, 2025 | $3.98 | $4.02 | -1.0% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Vertex Pharmaceuticals Inc's market cap?
As of June 29, 2026, Vertex Pharmaceuticals Inc (VRTX) has a market capitalization of $124.70B.
What is Vertex Pharmaceuticals Inc's P/E ratio?
Vertex Pharmaceuticals Inc trades at a trailing price-to-earnings (P/E) ratio of 29.2. Its forward P/E is 25.8.
Does Vertex Pharmaceuticals Inc pay a dividend?
Vertex Pharmaceuticals Inc does not currently pay a dividend.
What sector is VRTX in?
Vertex Pharmaceuticals Inc is in the Healthcare sector, specifically the Biotechnology industry.
What was Vertex Pharmaceuticals Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Vertex Pharmaceuticals Inc reported revenue of $12.07B and net income of $3.95B.
Ask your own questions about VRTX
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.